サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1568039

ヒドロキシクロロキンの世界市場

Hydroxychloroquine

出版日
ページ情報
英文 293 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
ヒドロキシクロロキンの世界市場
出版日: 2024年10月11日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 293 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヒドロキシクロロキンの世界市場は2030年までに13億米ドルに達する見込み

2023年に10億米ドルと推定されるヒドロキシクロロキンの世界市場は、分析期間2023-2030年にCAGR 3.1%で成長し、2030年には13億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるマラリア疾患は、CAGR 4.5%を記録し、分析期間終了時には6億4,400万米ドルに達すると予測されます。関節リウマチ疾患セグメントの成長率は、分析期間中CAGR 2.1%と推定されます。

米国市場は2億8,420万米ドル、中国はCAGR6.3％で成長予測

米国のヒドロキシクロロキン市場は、2023年に2億8,420万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 6.3%で推移し、2030年には2億6,830万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8%と2.4%と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界のヒドロキシクロロキン市場- 主要動向と促進要因まとめ

ヒドロキシクロロキンとは何か、なぜ世界的に注目されているのか？

ヒドロキシクロロキンは元々マラリア治療のために開発された薬であるが、その後ループスや関節リウマチなどの自己免疫疾患の治療に広く使用されるようになった。ヒドロキシクロロキンは、免疫系を調節し、炎症を抑えることにより作用し、これらの慢性疾患に対する効果的な治療選択肢となります。化学的には、ヒドロキシクロロキンはクロロキン（別の抗マラリア薬）の誘導体であるが、より安全性が高く、副作用が少ないと考えられています。近年、ヒドロキシクロロキンは、COVID-19の治療薬として使用される可能性があるとして、物議を醸し、広く議論されているため、かつてないほど世界の注目を集めています。パンデミックの初期には、ウイルスの複製を阻害し、免疫反応を調節することによって、ウイルスの重症度を軽減するのに役立つかもしれないという予備的研究や逸話的証拠がいくつかあった。このため、この薬に対する需要が急増し、世界の関心が高まり、備蓄したり、医師が適応外で処方したりする国もあった。しかし、その後の大規模な臨床試験や科学的調査の結果はまちまちで、その有効性については大きな議論と混乱を招いた。世界保健機関（WHO）や米国食品医薬品局（FDA）などの規制機関は、当初は緊急使用許可を出したが、決定的な証拠がないことや潜在的な安全性の懸念を理由に、後にそれを取り消しました。ヒドロキシクロロキンは、このような継続的な監視により、医学界だけでなく、一般社会でも脚光を浴び続けており、最近最も話題となっている医薬品の一つです。

ヒドロキシクロロキンの使用者、主な医療用途は？

ヒドロキシクロロキンは、主にループスや関節リウマチなどの自己免疫疾患に対する疾患修飾性抗リウマチ薬（DMARD）として、承認された適応症で広く使用され続けています。ヒドロキシクロロキンは、これらの疾患患者が慢性的な炎症と過剰な免疫反応を経験するのを助け、再燃を予防し症状を管理します。特にループス患者にとって、この薬は非常に貴重であることが証明されており、皮膚の発疹、関節痛、疲労をコントロールし、重篤な疾患発現に伴う臓器障害を予防するのに役立っています。関節リウマチへの使用もよく知られており、関節の腫れや痛み、自己免疫活動によって引き起こされる長期的なダメージを軽減するのに役立っています。これらの確立された用途以外にも、抗マラリア薬としてのKEYWORDの役割は、マラリアが流行している地域では依然として重要であるが、現在では、予防のためや、新しい抗マラリア薬に対する耐性が懸念されない特定の場合に主に使用されています。COVID-19のパンデミックは、抗ウイルス作用の可能性を示唆する初期の報告に後押しされ、ヘルスケア専門家と一般市民の間で適応外使用の急増をもたらしました。この適応外使用は、医薬品不足を招き、慢性疾患でこの医薬品に依存している患者のアクセスに関する懸念を引き起こしました。このような論争にもかかわらず、シェーグレン症候群やサルコイドーシスを含む他の様々な疾患において、KEYWORDの免疫調節作用や抗炎症作用が研究対象として検討され続けています。このように、COVID-19治療におけるヒドロキシクロロキンの位置づけはほとんど否定されているが、ヒドロキシクロロキンは、世界中で自己免疫疾患に苦しむ何百万人もの人々にとって重要な薬であることに変わりはないです。

ヒドロキシクロロキンを取り巻く課題と論争とは？

ヒドロキシクロロキンは、科学的不確実性、政治的力学、一般大衆の誤った情報の組み合わせにより、非常に荷電した複雑な論争の中心となっています。最大の課題の一つは、承認された適応症以外の用途における安全性と有効性をめぐるデータの矛盾です。COVID-19の大流行の初期には、小規模な観察研究や試験管内実験で潜在的な効果が示唆され、適応外使用が相次いです。しかし、より大規模なランダム化比較試験が実施されるにつれ、その多くは有意な臨床的利益を示せず、中には副作用、特に不整脈やQT延長のような心血管系合併症を報告するものさえあった。このような結果の一貫性のなさは、ヘルスケア提供者と一般大衆の双方に混乱をもたらし、科学的研究と規制機関に対する信頼を損なった。さらに混乱に拍車をかけたのは、この薬が政治的に利用されたことです。著名人による推奨や誤った情報キャンペーンによって、両極化した議論が展開され、一般市民の認識はさらに泥沼化しました。最初の誇大広告は、買いだめや備蓄、場合によっては自己投薬の蔓延につながり、その結果、中毒や入院を引き起こしました。このような状況は、狼瘡や関節リウマチのような慢性疾患でヒドロキシクロロキンに依存している患者にとって、欠品によって治療計画が中断されるという重大な課題をもたらしました。さらに、ヒドロキシクロロキンに関する規制当局の判断は一貫しておらず、FDAや欧州医薬品庁（EMA）などの機関は緊急使用許可を出したり、取り消したりしています。このような規制の行き違いは、科学的検証のプロセスや、公衆衛生の意思決定における政治の役割について、より広範な問題を提起しています。このような論争にもかかわらず、ヒドロキシクロロキンの承認された使用法における安全性プロファイルは、過去数年の激動によってその評判が影響を受けたことは否定できないもの、依然として十分に確立されています。

ヒドロキシクロロキンへの継続的な関心の要因は何か？

ヒドロキシクロロキンへの関心と調査の成長は、その確立された治療効果、進行中の科学的調査、費用対効果の高い治療オプションの探求に関連するいくつかの要因によってもたらされています。主な原動力の一つは、自己免疫疾患に対する安全で効果的な治療薬として長年使用されてきたことであり、ループスや関節リウマチといった疾患の治療における主役となっています。これらの慢性疾患の患者にとって、ヒドロキシクロロキンは、他の免疫抑制剤と比較して比較的良好な副作用プロファイルを有しながら、疾患活動性を低下させ、合併症を予防する信頼性の高い薬剤であることが証明されています。この確立された有効性により、シェーグレン症候群やサルコイドーシスなど、炎症や免疫調節異常が重要な役割を果たす他の免疫介在性疾患への応用の可能性を探る関心が持続しています。また、手頃な価格で広く入手可能であることも、関心を高める重要な要因となっています。ジェネリック医薬品であるヒドロキシクロロキンは、新しい免疫調節薬や生物学的製剤に比べて安価であるため、特に医療資源が限られている中低所得国では魅力的な選択肢となります。さらに、COVID-19での使用をめぐる論争が、逆説的にその薬理学的特性に関するより多くの研究に拍車をかけており、現在ではその免疫調節効果に寄与する作用機序の正確な理解に焦点を当てた研究もあります。研究者たちは、サイトカインレベルへの影響、血栓性合併症の予防における潜在的効果、免疫反応に関与する様々なシグナル伝達経路への影響などを調べています。その結果、ヒドロキシクロロキンは、その既知の用途だけでなく、免疫調節治療の薬理学的展望におけるより広範な役割においても、科学的探究の対象であり続けています。

調査対象企業の例（全56件）

  • Abcam PLC
  • Amneal Pharmaceuticals, Inc.
  • Apotex, Inc.
  • Daicel Chiral Technologies（India）Pvt. Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Hetero Healthcare Ltd.
  • Ipca Laboratories Ltd.
  • Lifevision Healthcare
  • Lupin Ltd.
  • MilliporeSigma

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP24095

Global Hydroxychloroquine Market to Reach US$1.3 Billion by 2030

The global market for Hydroxychloroquine estimated at US$1.0 Billion in the year 2023, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Malaria Disease, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$644.0 Million by the end of the analysis period. Growth in the Rheumatoid Arthritis Disease segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$284.2 Million While China is Forecast to Grow at 6.3% CAGR

The Hydroxychloroquine market in the U.S. is estimated at US$284.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$268.3 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Hydroxychloroquine Market - Key Trends and Drivers Summarized

What is Hydroxychloroquine, and Why Has It Garnered Global Attention?

Hydroxychloroquine is a medication that was originally developed to treat malaria but has since become widely used in the management of autoimmune disorders such as lupus and rheumatoid arthritis. It works by modulating the immune system and reducing inflammation, making it an effective therapeutic option for these chronic conditions. Chemically, hydroxychloroquine is a derivative of chloroquine, another antimalarial drug, but it is considered to have a better safety profile and fewer side effects. In recent years, hydroxychloroquine has gained unprecedented global attention due to its controversial and widely debated use as a potential treatment for COVID-19. Early in the pandemic, some preliminary studies and anecdotal evidence suggested that it might help in reducing the severity of the virus by inhibiting viral replication and modulating the immune response. This sparked a surge in demand and global interest in the drug, with some countries stockpiling it and doctors prescribing it off-label. However, subsequent large-scale clinical trials and scientific investigations yielded mixed results, leading to significant debate and confusion about its efficacy. Regulatory agencies like the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) initially issued emergency use authorizations but later revoked them, citing a lack of conclusive evidence and potential safety concerns. This ongoing scrutiny has kept hydroxychloroquine in the spotlight, not just in the medical community but also in public discourse, making it one of the most talked-about drugs of recent times.

Who is Using Hydroxychloroquine, and What Are Its Main Medical Applications?

Hydroxychloroquine continues to be widely used in its approved indications, primarily as a disease-modifying antirheumatic drug (DMARD) for autoimmune conditions like lupus and rheumatoid arthritis. Patients suffering from these disorders often experience chronic inflammation and an overactive immune response, and hydroxychloroquine helps by modulating these processes to prevent flare-ups and manage symptoms. For lupus patients, in particular, the drug has proven to be invaluable, helping to control skin rashes, joint pain, and fatigue, and preventing organ damage associated with severe disease manifestations. Its use in rheumatoid arthritis is also well-documented, where it helps reduce joint swelling, pain, and the long-term damage caused by autoimmune activity. Beyond these established applications, hydroxychloroquine’s role as an antimalarial agent remains relevant in regions where malaria is endemic, although it is now largely used for prevention and in specific cases where resistance to newer antimalarials is not a concern. The COVID-19 pandemic brought a surge of off-label use among both healthcare professionals and the general public, fueled by early reports suggesting potential antiviral properties. This off-label usage led to shortages and raised concerns about access for patients who depend on the drug for chronic conditions. Despite the controversies, hydroxychloroquine’s immunomodulatory and anti-inflammatory properties have kept it under consideration for research in various other diseases, including Sjögren's syndrome and sarcoidosis. Thus, while its place in COVID-19 treatment has been largely debunked, hydroxychloroquine remains a critical medication for millions suffering from autoimmune diseases worldwide.

What Challenges and Controversies Surround Hydroxychloroquine?

Hydroxychloroquine has been at the center of a highly charged and complex controversy, driven by a combination of scientific uncertainty, political dynamics, and public misinformation. One of the biggest challenges is the conflicting data surrounding its safety and efficacy for uses beyond its approved indications. Early in the COVID-19 pandemic, small observational studies and in vitro experiments suggested potential benefits, leading to a wave of off-label use. However, as larger randomized controlled trials were conducted, many failed to show any significant clinical benefits, and some even reported adverse effects, particularly cardiovascular complications like arrhythmias and QT prolongation. This inconsistency in results led to confusion among both healthcare providers and the public, eroding trust in scientific research and regulatory bodies. Adding to the confusion was the politicization of the drug, with high-profile endorsements and misinformation campaigns creating a polarized debate that further muddied public perception. The initial hype led to widespread hoarding, stockpiling, and in some cases, self-medication, which resulted in toxicity and hospitalizations. This situation posed significant challenges for patients who rely on hydroxychloroquine for chronic conditions like lupus and rheumatoid arthritis, as shortages disrupted their treatment regimens. Additionally, regulatory decisions regarding hydroxychloroquine have been inconsistent, with agencies such as the FDA and the European Medicines Agency (EMA) issuing and then retracting emergency use authorizations. This regulatory back-and-forth has raised broader questions about the process of scientific validation and the role of politics in public health decision-making. Despite these controversies, hydroxychloroquine’s safety profile for its approved uses remains well-established, though its reputation has been undeniably affected by the turbulence of the past few years.

What Factors Are Driving the Continued Interest in Hydroxychloroquine?

The growth in interest and research into hydroxychloroquine is driven by several factors related to its established therapeutic benefits, ongoing scientific inquiries, and the quest for cost-effective treatment options. One of the main drivers is its long-standing use as a safe and effective treatment for autoimmune disorders, making it a mainstay in the management of diseases like lupus and rheumatoid arthritis. For patients with these chronic conditions, hydroxychloroquine has proven to be a reliable medication that reduces disease activity and prevents complications, with a relatively favorable side effect profile compared to other immunosuppressive drugs. This established efficacy has sustained interest in exploring its potential applications in other immune-mediated diseases, such as Sjögren’s syndrome and sarcoidosis, where inflammation and immune dysregulation play a key role. Another key factor driving interest is its affordability and widespread availability. As a generic drug, hydroxychloroquine is inexpensive compared to newer immunomodulatory or biologic therapies, making it an attractive option, particularly in low- and middle-income countries where healthcare resources are limited. Moreover, the controversies surrounding its use in COVID-19 have paradoxically fueled more research into its pharmacological properties, with some studies now focusing on understanding the exact mechanisms of action that contribute to its immunomodulatory effects. Researchers are looking into its impact on cytokine levels, potential benefits in preventing thrombotic complications, and its influence on various signaling pathways involved in immune response. As a result, hydroxychloroquine remains a subject of scientific inquiry, not just for its known applications, but also for its broader role in the pharmacological landscape of immunomodulatory treatments.

Select Competitors (Total 56 Featured) -

  • Abcam PLC
  • Amneal Pharmaceuticals, Inc.
  • Apotex, Inc.
  • Daicel Chiral Technologies (India) Pvt. Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Hetero Healthcare Ltd.
  • Ipca Laboratories Ltd.
  • Lifevision Healthcare
  • Lupin Ltd.
  • MilliporeSigma

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Hydroxychloroquine - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Malaria in Endemic Regions Drives Growth in the Hydroxychloroquine Market
    • Increased Use of Hydroxychloroquine in the Treatment of Autoimmune Disorders Expands Market Potential
    • Growing Adoption for Rheumatoid Arthritis and Lupus Erythematosus Fuels Demand
    • Emerging Research on Hydroxychloroquine's Role in Managing Inflammatory Conditions Strengthens Market Scope
    • Rising Demand for Hydroxychloroquine in Developing Countries for Malaria Control Sustains Market Growth
    • Growing Emphasis on Chronic Disease Management Drives Long-Term Use of Hydroxychloroquine
    • Shifting Focus Towards Personalized Medicine in Autoimmune Disease Management Creates New Opportunities
    • Growing Use of Hydroxychloroquine in Combination Therapies Fuels Research and Development Initiatives
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hydroxychloroquine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hydroxychloroquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Malaria Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Malaria Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Malaria Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Rheumatoid Arthritis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Rheumatoid Arthritis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Homecare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Hydroxychloroquine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Hydroxychloroquine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Hydroxychloroquine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Hydroxychloroquine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION